Overview

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Status:
Recruiting

Trial end date:
2025-02-10

Target enrollment:
0

Participant gender:
All

Summary

The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing spondylitis [JoAS]) and juvenile psoriatic arthritis (JPsA).

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Adalimumab
Ixekizumab

Criteria

Inclusion Criteria:

- Participants must have active juvenile idiopathic arthritis (categories of enthesitis
related arthritis or juvenile psoriatic arthritis)

- Participants must have weight of at least 10 kilograms (Kg), age starting at 2 years
for participants with juvenile psoriatic arthritis and starting at 6 years for
participants with enthesitis related arthritis

- Participants must have all immunizations up-to-date in agreement with current
immunization guidelines, in the opinion of the investigator

Exclusion Criteria:

- Participants must not have active or history of inflammatory bowel disease

- Participants must not have active uveitis

- Participants must not have active or latent tuberculosis

- Participants must not have an active infection

- Participants must not have concurrent use of biologic agents for the treatment of the
juvenile idiopathic arthritis